Menu

Evaluating an investigational drug for Super-Refractory Status Epilepticus

Please submit your other inquiries here.

Note: You must be a health care professional (HCP) to fill out this form. By clicking submit, you are confirming you are a health care professional. Please do not include any patient-identifying information.

Specify Your Inquiry (A selection is required.)

Please fill out this form if you have a potential patient for the Phase 3 SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus (STATUS) Trial.

Note: You must be a health care professional (HCP) to fill out this form. By clicking submit, you are confirming you are a health care professional. Please do not include any patient-identifying information.

Please fill out this form if you are interested becoming a site or investigator for the Phase 3 SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus (STATUS) Trial.

Note: You must be a health care professional (HCP) to fill out this form. By clicking submit, you are confirming you are a health care professional. Please do not include any patient-identifying information.

Submitting…

SRSE is a rare, life-threatening condition with high morbidity and mortality rates

Currently there are no FDA-approved treatments indicated for SRSE. The STATUS Trial will evaluate the safety and efficacy of SAGE-547, an investigational medicine, as a potential treatment for SRSE. SAGE-547 has been granted fast track and orphan drug designations by the FDA to expedite clinical development and review for SRSE.

Learn more about SAGE-547 and the Phase 3 STATUS Trial, including trial design and how to identify potential patients.

Learn about the STATUS Trial
Sage Therapeutics

© 2015 SAGE Therapeutics. Terms of Use